A kernel-based integration of genome-wide data for clinical decision support

Table 5 Features for prostate cancer selected by MG and known to be involved in this type of cancer

Outcome*	Gene/CNV	Hits^†	Region	Function	Up/down^‡	Reference
G	SFRP4	55	7p14.1	Inhibitor of PT growth/invasion	Up	[55]
G	VCAN	55	5q14.3	Contributor to PC pathology	Up	[82]
G	ALOX15B	36	17p13.1	Suppressor of PT development	Down	[54]
S	MAGEA4	50	Xq28	Only expressed in PC (diagnosis and therapy)	Down	[83]
S	ANPEP	50	15q25-q26	PT cell invasion	Down	[84]
S	POU4F1	50	13q31.1	PC cell growth	Down	[85]
S	CXCL14	48	5q31	Inhibitor of PT growth	Up	[56]
S	RNASEL	48	1q25	Polymorphic changes as tumor; suppressor in hereditary PC	Up	[62]
S	GDEP	41	4q21.1	Prostate-specific gene	Down	[86]
M	ERG	50	21q22.3	Proto-oncogene; early prostate carcinogenesis	Up	[57]
M	AREG	49	4q13-q21	PC progression/growth via TARP	Down	[87]
M	VAV3	49	1p13.3	Oncogene; PC development/progression	Up	[59]
M	ADAMTS1	26	21q21.2	Negatively affected by TGFbeta1, which increases VCAN-expression	Down	[82]
R	AZGP1	29	7q22.1	Inversely associated to tumor stage; predictor of biochemical recurrence	Down	[88]
R	TIAM1	29	21q22.1-11	Predictor of decreased disease-free survival/recurrence	Up	[60]
R	FGG	28	4q28	PC cell growth	Down	[89]
R	ATF3	26	1q32.3	Inversely related to invasion/angiogenesis; positively correlated to metastases	Down	[90]
R	JAG1	26	20p12.1-11.23	Cell growth/progression/metastasis	Up	[61]
R	ERG	14	21q22.3	Proto-oncogene; early prostate carcinogenesis	Up	[57]
R	ALOX15B	14	17p13.1	Suppressor of PT development	Down	[54]

*G, GRADE; S, STAGE; M, METASTASIS; R, RECURRENCE. ^†Number of occurrences of the gene/CNV in all LOO iterations (number of LOO iterations for G = 55, S = 50, M = 50, R = 29). ^‡Up/down-regulation in high-grade with respect to low-grade; advanced stage with respect to early stage; metastasis with respect to no metastasis; recurrence with respect to no recurrence. PC, prostate cancer; PT, prostate tumor.

ISSN: 1756-994X